目的 探討散風通竅滴丸治療變應性鼻炎肺經伏熱證的臨床療效。方法 選取2020年3月-2021年6月北京中西醫(yī)結合醫(yī)院收治的91例變應性鼻炎肺經伏熱證患者，按照隨機分組法將患者分為鼻淵通竅顆粒組（30例）、氯雷他定組（30例）和散風通竅滴丸組（31例）。鼻淵通竅顆粒組口服鼻淵通竅顆粒，1袋/次，3次/d。氯雷他定組口服氯雷他定片，10 mg/次，1次/d。散風通竅滴丸組口服散風通竅滴丸，20丸/次，3次/d。3組均連續(xù)治療1個月。觀察3組臨床療效，比較3組中醫(yī)證候積分、鼻結膜炎生活質量量表（RQLQ）評分、血清細胞因子的變化。結果 治療后，散風通竅滴丸組綜合療效總有效率是90.32%，顯著高于鼻淵通竅顆粒的76.67%和氯雷他定組的83.33%（P<0.05）；散風通竅滴丸組單項癥狀、體征療效的總有效率是93.55%，顯著高于鼻淵通竅顆粒的83.33%和氯雷他定組的86.67%（P<0.05）。治療后，3組治療前后中醫(yī)證候評分均較同組治療前顯著降低（P<0.05）；散風通竅滴丸組鼻塞、鼻黏膜腫脹評分顯著低于鼻淵通竅顆粒組和氯雷他定組；散風通竅滴丸組流清/黏稠涕評分、口干評分、舌紅苔薄白/黃評分、脈數(shù)評分顯著低于氯雷他定組（P<0.05）。治療后，3組RQLQ評分均較治療前顯著降低（P<0.05）；且治療后，散風通竅滴丸組RQLQ評分顯著低于氯雷他定（P<0.05）。治療后，3組患者血清白細胞介素-4（IL-4）、白細胞介素-13（IL-13）水平均較治療前顯著降低（P<0.05）；治療后3組患者血清炎性因子水平比較差異無統(tǒng)計學意義。治療期間，鼻淵通竅顆粒組不良反應發(fā)生率是6.67%，氯雷他定組是13.33%，散風通竅滴丸組是3.23%，氯雷他定組不良反應發(fā)生率顯著高于散風通竅滴丸組（P<0.05）。結論 散風通竅滴丸是一種安全有效的治療變應性鼻炎肺經伏熱證的藥物，可明顯改善各項中醫(yī)證候指標，顯著改善變應性鼻炎鼻塞和鼻黏膜腫脹癥狀，能降低血清IL-4和IL-13水平。

Objective To explore the clinical effect of Sanfeng Tongqiao Dropping Pills in treatment of allergic rhinitis lung meridian latent heat syndrome. Methods A total of 91 patients with allergic rhinitis lung meridian latent heat syndrome admitted to Beijing Hospital of Integrated Traditional Chinese and Western Medicine from March 2020 to June 2021 were selected and divided into Biyuan Tongqiao Granules group (30 cases), loratadine group (30 cases), and Sanfeng Tongqiao Dropping Pills group (31 cases) according to randomization method. Patients in Biyuan Tongqiao Granule group were po administered with Biyuan Tongqiao Granules, 1 bag/time, three times daily. Patients in loratadine group were po administered with Loratadine Tablets, 10 mg/time, once daily. Patients in Sanfeng Tongqiao Dropping Pill group were po administered with Sanfeng Tongqiao Dropping Pills, 20/time, three times daily. Patients in three groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the changes of TCM syndrome score, RQLQ score and serum cytokines in three groups were compared. Results After treatment, the total effective rate of Sanfeng Tongqiao Dropping Pill group was 90.32%, which was significantly higher than that of Biyuan Tongqiao Granules (76.67%) and loratadine group (83.33%) (P < 0.05). The total effective rate of single symptom and sign in Sanfeng Tongqiao Dropping Pills group was 93.55%, which was significantly higher than that of Biyuan Tongqiao Granules (83.33%) and loratadine group (86.67%) (P < 0.05). After treatment, the TCM syndrome scores of 3 groups before and after treatment were significantly lower than those before treatment (P < 0.05); Nasal congestion and mucosal swelling scores of Sanfeng Tongqiao Dropping Pill group were significantly lower than those of Biyuan Tongqiao Granule group and loratadine group. The scores of run-clear/sticky nose, dry mouth, red tongue and thin white/yellow tongue and pulse number in Sanfeng Tongqiao Dropping Pill group were significantly lower than those in loratadine group (P < 0.05). After treatment, RQLQ score in 3 groups was significantly lower than before treatment (P < 0.05). After treatment, RQLQ score of Sanfeng Tongqiao Dropping Pill group was significantly lower than that of loratadine group (P < 0.05). After treatment, serum IL-4 and IL-13 levels in 3 groups were significantly decreased compared with before treatment (P < 0.05). After treatment, there was no significant difference in serum inflammatory factors among 3 groups. During treatment, the incidence of adverse reactions was 6.67% in the Biyuan Tongqiao Granule group, 13.33% in the loratadine group and 3.23% in the Sanfeng Tongqiao Dropping Pill group. The incidence of adverse reactions in the loratadine group was significantly higher than that in the Sanfeng Tongqiao Dropping Pills group (P< 0.05). Conclusion Sanfeng Tongqiao Dropping Pills is a safe and effective drug for the treatment of allergic rhinitis lung meridian heat syndrome, and can significantly improve various TCM syndrome indicators, significantly improve the symptoms of allergic rhinitis nasal congestion and nasal mucosal swelling, and can reduce serum IL-4 and IL-13 levels.

R987